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Summary
Following implementation of the one-dose varicella vaccination program in the United
States in 1995, varicella vaccination coverage has steadily increased and the number of varicella 
cases has decreased. However, despite the increasing use of varicella vaccine, outbreaks of 
varicella have continued to occur, even in settings with high vaccination coverage. Thus, in June 
2006, a second dose of varicella vaccine was added to the routine childhood vaccination program
to assist, in part, with outbreak prevention and control.  
To improve existing knowledge about the epidemiology of varicella and to have a basis 
for refining varicella vaccination policy, it is important to monitor and investigate varicella 
outbreaks. These guidelines for the control and investigation of such outbreaks were developed 
by the Centers for Disease Control and Prevention’s (CDC’s) National Center for Immunization 
and Respiratory Diseases (NCIRD) with input from state and local public health departments. 
Public health officials should implement appropriate responses to reports of varicella cases to 
determine if an outbreak exists and, if so, to evaluate its scope and implement control measures 
appropriate to the outbreak setting. 
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I. INTRODUCTION
Before licensure of the varicella vaccine, varicella was a common childhood disease, 
causing about 4 million cases, including an average of 10,500 hospitalizations and 105 deaths, 
each year [1–3]. The varicella vaccine was licensed for use in the United States in 1995 and was 
recommended by the Advisory Committee on Immunization Practices (ACIP) and the American 
Academy of Pediatrics (AAP) for routine use in healthy children 12–18 months of age and for 
older susceptible children and adults [4, 5]. In 2006, national 1-dose varicella vaccination 
coverage among children 19–35 months of age was 89% [6] and varicella-related morbidity and 
mortality had declined significantly following implementation of the 1-dose varicella vaccination 
program. The incidence of disease decreased 90% between 1995 and 2005, with the greatest 
decline in children and adolescents [7]. National varicella hospitalizations declined 88% during 
1994–2002 [8], and age-adjusted mortality rates decreased 66% from 1990–1994 to 1999–2001, 
with the greatest decline (92%) in children 1–4 years of age [3].  
Recommendations for the prevention of varicella were updated in 2006 to include a 
routine two-dose schedule for children; the first dose is recommended at 12–15 months of age 
and the second dose at 4–6 years of age, with catch-up vaccination for all persons without 
evidence of immunity to varicella and for one-dose vaccine recipients [9]. One of the rationales 
for the second-dose recommendation was to reduce the number of varicella outbreaks because of
the burden they caused on public health personnel, schools, and families. Therefore, tracking 
outbreaks through existing case-based surveillance will help states and CDC monitor the impact 
of this new recommendation.   
As overall disease incidence declines, the risk for exposure to varicella-zoster virus 
(VZV) decreases, leading to susceptible (unvaccinated and vaccinated) children aging into 
adolescence and adulthood. Although the total number of varicella cases is declining, a shift of 
the remaining varicella disease burden to middle school years is being observed. In 1995, the 
median age of varicella infection ranged from 3-5 years in vaccinated persons and from 5-6 years 
in unvaccinated persons. By 2005, the median age increased to 6–8 years in vaccinated persons 
and 13–19 years in unvaccinated persons [7]. 
As the age of infection increases, varicella outbreaks may occur more frequently in 
middle schools, high schools, and colleges. Implementation of recommended catch-up 
vaccination for older children and adolescents and varicella vaccination requirements for day 
care, elementary, middle, and high school, and college entry will prevent increasing 
susceptibility and subsequent outbreaks in these age groups [9]. Achieving high immunization 
levels in day care centers, schools, and colleges is important because transmission of infectious 
diseases like varicella is facilitated by the increased contact rates among students [10]. In the 
United States, school requirements have proven to be an extremely effective strategy for 
achieving high vaccination coverage among school-aged children [11]. As of September 2007, 
48 states and the District of Columbia had implemented requirements that children entering day 
care or school must have received either one dose of varicella vaccine or have other evidence of 
immunity to varicella. Twenty-six states have requirements for entry to middle or high school 
[CDC unpublished data, 12]. States are in the process of transitioning to the two-dose varicella 
vaccination school entry requirements for elementary schools; the number of states with college
entry requirements is not known.  
Investigations of varicella outbreaks in schools and other settings in the vaccine era will 
improve our knowledge of the epidemiology of varicella, assess virus transmission patterns, 
describe disease burden and risk factors for severe varicella, provide estimates of varicella 
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vaccine effectiveness for two versus one dose of vaccine, and identify risk factors for vaccine 
failure. In addition, monitoring the number and size of varicella outbreaks will help to assess 
impact of the second-dose recommendation. These data will facilitate the development and 
refinement of appropriate public health interventions to control and prevent future varicella 
outbreaks and further reduce varicella morbidity and mortality.
II. BACKGROUND  
Varicella (chickenpox) is the disease that results from primary infection with the 
varicella-zoster virus (VZV). It is a highly contagious rash illness that is transmitted from person 
to person by direct contact with patients with either varicella or herpes zoster (HZ) or by airborne 
spread (from respiratory secretions or aerosolized vesicular fluid from skin lesions). Secondary 
attack rates among susceptible household contacts occur in 65% to 86% of cases [13-15]. The 
average incubation period is 14–16 days (range, 10–21 days). Persons with varicella are 
considered infectious from 1 to 2 days before the rash appears and until all lesions are crusted 
over (average range, 4–7 days after rash onset). Infants, adolescents, adults, and 
immunocompromised persons are at higher risk for complications. Persons with underlying 
immunocompromising medical conditions (e.g., cancer, HIV/AIDS) are especially likely to have 
more severe disease and a longer time to crusting of lesions; thus, they may shed virus from skin 
lesions for a prolonged period [16]. Severe complications of varicella include secondary bacterial 
infections, dehydration, pneumonia, encephalitis, and cerebellar ataxia, all of which may result in 
death. 
Varicella in vaccinated persons (i.e., breakthrough disease) is a varicella-like rash that 
occurs more than 42 days after vaccination. The disease is usually mild with a shorter duration of 
illness, less constitutional symptoms, and fewer than 50 skin lesions (sometimes even <10; 
compared with approximately 250–500 lesions in unvaccinated healthy persons). Rash is 
atypical, often maculopapular, with few or no vesicles. However, breakthrough varicella disease 
in vaccinated persons has been shown to be contagious. Seward et al. [15] demonstrated that 
vaccinated persons with <50 lesions were one-third as contagious as unvaccinated persons, but 
vaccinated persons with ≥50 lesions were just as contagious as unvaccinated persons. Varicella 
outbreaks have been documented in highly vaccinated populations [17-20] and vaccinated case-
patients acted as index cases in several outbreaks. Although breakthrough varicella is generally 
mild, approximately 25% of case-patients may have >50 lesions and clinical features similar to 
those among unvaccinated persons. However, serious complications have been reported among 
persons who developed <50 lesions [21].  
Pre- and post-licensure studies have demonstrated vaccine effectiveness of one dose of 
the varicella vaccine to be about 80–85%, on average, for prevention of disease of any severity 
and >95% for prevention of severe disease [17-19, 22-35]. In a clinical trial comparing one 
versus two doses of varicella vaccine, for disease of any severity, the risk for developing
breakthrough varicella was >3-fold lower among two-dose vaccinees compared with one-dose 
vaccinees [32]. Vaccine efficacy of two doses was significantly higher compared with that of one 
dose (98% vs 94%; p<0.001) [32]. Studies are needed to assess the field effectiveness of two 
doses; however, on the basis of results from the clinical trial, it is expected to be higher than the 
effectiveness of one dose. 
After primary infection as varicella, VZV resides in the cell bodies associated with spinal 
nerves. Reactivation of latent VZV results in HZ (shingles). Clinical features of HZ include a 
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localized pruritic, often painful, vesicular rash that generally appears unilaterally in one or more 
dermatomes [36]. Persons with HZ are infectious during the vesicular stages of rash; the rash 
typically crusts over within 7–10 days but may take from 2 to 6 weeks to heal completely 
[36,37]. Immunocompromised persons are at increased risk of disseminated or more severe 
disease. Localized HZ is approximately one-fifth as infectious as varicella or disseminated HZ 
[38], but transmission of VZV has been reported. Reports indicated the rare occurrence of 
airborne transmission of VZV from HZ case-patients in healthcare settings [39-41]. HZ case-
patients have also been identified as the index case in outbreaks of varicella [42].  
III. REPORTING 
At the beginning of the varicella vaccination program in 1995, active surveillance sites 
were established to assist with monitoring. However, to fully assess the impact of the varicella 
vaccination program, national surveillance is needed. 
As a first step in establishing national varicella surveillance, varicella deaths became 
nationally notifiable in 1999 [43]. In 2002, the Council of State and Territorial Epidemiologists 
(CSTE) recommended that states begin reporting individual cases of varicella by 2003 and 
implement state-wide case-based reporting by 2005 [44]. The three initial core variables 
recommended by CDC for case-based reporting included age, vaccination status, and severity of 
disease (based on number of lesions). However, states conducting case-based surveillance should 
now be collecting standard demographic, clinical, and epidemiologic data on each case. States 
unable to collect these data should collect, at a minimum, the three key variables mentioned 
above. It is also important to collect information on the case outcome (i.e., whether the patient 
was hospitalized or died). Probable and confirmed cases of varicella should be reported to CDC. 
In 2007, 34 states reported varicella cases to the National Notifiable Diseases Surveillance 
System (NNDSS). To report varicella-specific data, a varicella messaging guide has been created 
to inform states on how to develop a message to extract the varicella variables from their 
surveillance system and send to CDC. The guide is available in CDC’s Varicella Notification 
Message Mapping Guide . State and local health departments rely on healthcare providers, 
public health workers, and school nurses to report varicella cases and related deaths. For 
information on the specific varicella reporting requirements for a particular state, contact the 
local or state health department.  
Tracking the number and size of varicella outbreaks through existing varicella case-based 
surveillance is another varicella surveillance strategy that can be used to monitor the impact of 
the two-dose recommendation. For states that have not yet established varicella case-based 
reporting, tracking only the number and size of varicella outbreaks may be a feasible alternative 
until case-based reporting is established. Reporting of varicella outbreaks can be facilitated in 
states with mandatory reporting of outbreaks of all reportable diseases in the state. Nineteen 
states are currently conducting varicella outbreak surveillance which includes collecting case-
based data on cases associated with varicella outbreaks. A sample worksheet for monitoring 
varicella outbreaks is available in Appendix A.  
IV. CASE DEFINITION AND CLASSIFICATION 
The following case definitions were approved by CSTE for varicella disease in 1999 and for 
varicella-related deaths in 1998 [43,45]. 
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Varicella clinical case definition. An illness with acute onset of diffuse (generalized) 
maculopapulovesicular rash without other apparent cause. In vaccinated persons who 
develop varicella more than 42 days after vaccination (i.e., breakthrough disease), the rash 
may by atypical in appearance (maculopapular with few or no vesicles). 
Varicella case classification. 
• Probable. A case that meets the clinical case definition, is not laboratory confirmed, and 
is not epidemiologically linked to another probable or confirmed case. 
• Confirmed. A case that is laboratory confirmed or a case that meets the clinical case 
definition and is epidemiologically linked to a confirmed or a probable case. Note: Two 
probable cases that are epidemiologically linked are considered confirmed, even in the 
absence of laboratory confirmation.  
Varicella deaths classification.
• Probable. A probable case of varicella that contributes directly or indirectly to acute 
medical complications that result in death.
• Confirmed. A confirmed case of varicella that contributes directly or indirectly to acute 
medical complications that result in death.
Laboratory Criteria for Diagnosis
• Direct detection—the demonstration of VZV antigen by polymerase chain reaction (PCR) 
tests, by direct fluorescent antibody (DFA), or by isolation of VZV through viral culture 
from a clinical specimen. These viral detection methods are the laboratory methods of 
choice for confirmation of varicella disease. 
• Four-fold or greater rise in serum varicella immunoglobulin G (IgG) antibody level 
between acute and convalescent serum by a quantitative serologic assay. A four-fold rise 
in IgG antibodies might not occur in vaccinated persons [46]. 
• Serologic test results that are positive for varicella-zoster immunoglobulin M (IgM) 
antibody by IgM capture assay. However, there is not much experience with IgM 
antibody testing and the IgM response in unvaccinated persons. Even less information is 
available for vaccinated persons. 
V. LABORATORY DIAGNOSIS OF VARCELLA 
The mild or atypical presentation of breakthrough varicella coupled with the rarity of 
cases in unvaccinated persons (due to the continued decline of varicella incidence in the 
vaccination era) creates challenges for clinical diagnosis and emphasizes a need for laboratory 
confirmation of cases. It is important for healthcare providers to consider varicella as a possible 
diagnosis for case-patients who have atypical presentation (e.g., <50 lesions that are mainly 
macular) because suspicion of varicella disease (e.g., link to case in school) is needed before 
laboratory diagnosis is considered. All state public health laboratories now have the capacity to 
diagnose VZV disease by PCR. 
Genotyping of VZV is also important for certain situations. In addition, it helps with the 
understanding of transmission of endemic disease. Genotyping will identify the strain as vaccine 
or wild-type and will provide details for further characterization of the virus. Specimens for 
confirmation and genotyping can be sent to the National VZV Laboratory; this website includes 
a link to the VZV Specimen Collection Form, which must be included with each sample that is 
sent, and it includes a video demonstrating the techniques for collecting different specimens for 
varicella confirmation. Additional information about laboratory testing for varicella diagnosis, 
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including virus identification and isolation, serologic testing, and specimen collection, can be 
found in the Varicella chapter of the Vaccine Preventable Diseases Surveillance Manual. 
VI. DEFINITIONS
• Airborne transmission. Dissemination of airborne VZV-containing droplet nuclei or
particles in the respirable size range that remain infective over time and distance. VZV
carried in this manner may be dispersed by air currents and may be inhaled by susceptible
persons who have not had face-to-face contact with or been in the same room with an
infectious person [47].
• Direct contact transmission. Transfer of VZV from one infected person to another person
without a contaminated intermediate object or person [47].
• Droplet transmission. Also considered a form of contact transmission. Conjunctival, nasal,
or oral mucosa contact with VZV-containing droplets (size >5μm) generated from an
infected person (by coughing, sneezing, and talking or during certain medical procedures,
such as suctioning or bronchoscopy) and propelled a short distance (e.g., ≤3 feet) [47].
• Exposure. Close contact with an infectious person, such as close indoor contact (e.g., in the
same room) or face-to-face contact. Experts differ in their opinion about the duration of
contact; some suggest 5 minutes and others up to 1 hour, but do agree that it does not include
transitory contact [48].
• Evidence of immunity to varicella [9] includes
o 
o 
o 
o 
 
Documentation of age-appropriate vaccination 
Preschool-aged children aged ≥12 months: 1 dose 
Laboratory evidence of immunity 
Laboratory confirmation of disease. 
Serologic confirmation of immunity. Commercial assays (IgG) can be used to 
assess disease-induced immunity, but they lack sensitivity to always detect 
vaccine-induced immunity (i.e., they might yield false-negative results). 
Birth in the United States before 1980. For healthcare personnel, pregnant women, 
and immunocompromised persons, birth before 1980 should not be considered 
evidence of immunity; in such cases, the other criteria of evidence of immunity 
should be sought. 
Diagnosis or verification of a history of varicella disease by a healthcare
provider. For typical disease, diagnosis or verification of history of disease can be 
provided by any healthcare provider (e.g., school or occupational clinic nurse, nurse 
practitioner, physician assistant, or physician). For persons reporting a history of, or 
reporting with, atypical or mild cases, assessment by a physician or their designee is 
recommended, and one of the following should be sought: 1) an epidemiologic link to 
a typical varicella case or laboratory-confirmed case or 2) evidence of laboratory 
confirmation (if laboratory testing was performed at the time of acute disease). When 
such documentation is lacking, persons should not 
9 
 
 o
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
be considered as having a valid history of disease because other diseases can 
mimic mild atypical varicella.
Diagnosis or verification of a history of herpes zoster by a healthcare 
provider. 
• High risk person/contact. Someone at increased risk for complications from varicella 
disease because of their age or an underlying condition (e.g., immunocompromised 
persons, cancer patients, pregnant women, neonates whose mothers are not immune). 
• Incubation period. The period between exposure to VZV and onset of rash. The average 
incubation period for varicella is 14–16 days, with a range of 10–21 days.
• Index case. The first person with varicella identified in a chain of transmission. 
• Infectious period. The period during which an infected person sheds VZV, beginning 2 
days before rash onset until all lesions are crusted over or until no new lesions appear
within a 24-hour period (average range, 4-7 days).   
• Outbreak. The occurrence of ≥5 varicella cases that are related in place and 
epidemiologically linked. 
• Residential institution settings. May include settings like long-term care facilities, 
nursing homes, and group homes. 
• School settings. May include child care centers, elementary, middle, and/or high schools, 
or colleges/universities.
VII. RECOMMENDATIONS 
As varicella outbreaks continue to occur in the United States, states will need to prioritize 
investigations of outbreaks. State or local health departments should decide on the level of action 
required. Box 1 lists outbreaks that are considered high priority for control and investigation 
because they present the greatest risk of severe morbidity from varicella or may impact the 
community. Box 2 outlines strategies for the control and investigation of varicella outbreaks. 
These strategies are based on experience with varicella outbreaks in the United States and are 
presented for outbreaks in school, residential institution, and healthcare settings but can be 
applied to other setting. 
Identification of a single case of varicella should trigger appropriate intervention 
measures as such cases can be sources for potential outbreaks. Different settings may have 
specific internal guidelines for managing a single case of varicella (e.g., prisons [49]) and these 
guidelines should be observed to help prevent outbreaks in the particular settings. These present 
guidelines provide an overall approach to the control and investigation of varicella outbreaks 
among children in school settings and among adults in closed settings. Many circumstances 
surrounding outbreaks will vary and require modified approaches to meet practical limitations of 
the outbreak site. 
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Box 1: Varicella outbreaks for priority control and investigation by public health 
authorities
1. Outbreaks involving patients and staff in healthcare settings.  
2. Outbreaks involving patients with complications (e.g., pneumonia, encephalitis, invasive 
Group A streptococcal infection, or hemorrhagic complications) and/or hospitalizations (≥1 
case). 
3. Outbreaks involving persons at risk for severe varicella because of their age or an underlying 
condition (e.g., immunocompromised persons, cancer patients, pregnant women, neonates 
whose mothers are not immune).  
4. Outbreaks involving cases among persons vaccinated with two doses of varicella vaccine. 
Box 2. Steps for the control and investigation of outbreaks of varicella 
A. A single varicella case as a potential source for an outbreak 
B. Confirm the outbreak  
C. Identify cases
D. Implement varicella control measures  
1. Notification of the outbreak 
2. Exclusion or isolation of case-patients 
3. Management of persons without evidence of immunity
E. Conduct case investigations  
F. Establish surveillance for additional cases 
G. Analyze and interpret the data 
H. Develop a plan for preventing future varicella outbreaks 
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A. A Single Varicella Case as a Potential Source for an Outbreak 
The identification of a single case of varicella should trigger intervention measures 
because this case could lead to an outbreak. The first step is to exclude or isolate the case from
the setting (e.g., school) immediately. Next, a notification letter can be sent to those that may 
have been exposed to the case (e.g., in a school setting, the letter could be sent home with the 
children in the same classroom as the case). However, how broadly to distribute the notification 
letter for a single case will be up to the discretion of the health department or setting. The 
notification letter should alert the person to the possibility of exposure to varicella, describe the 
disease, recommend vaccination if the person is not already considered immune, and recommend 
exclusion if disease develops. Examples of exposure letters are available in Appendix B.
B. Confirm the Outbreak  
The first step in the control and investigation of a suspected varicella outbreak is to 
confirm that it is an outbreak. Physicians and public health professionals should make every 
effort to establish epidemiologic links for cases and obtain clinical specimens for laboratory 
testing. During an outbreak, laboratory confirmation of varicella is recommended for at least 
three to five cases (irrespective of the patients’ vaccination status), especially at the beginning of 
the outbreak. Laboratory confirmation of cases at the end of the outbreak is helpful to document 
the end of the outbreak. 
C. Identify Cases 
Once an outbreak of varicella is confirmed, the affected population should be surveyed to 
identify all cases. Case finding is an important step for outbreak control and can be done 
concurrently with implementing control measures. Key information that should be collected from
case-patients includes age, vaccination status, disease history, and underlying medical 
conditions. For outbreaks that are fully investigated, the same information should also be 
collected from persons without varicella. An example of a survey is available in Appendix C. 
D. Implement Varicella Control Measures 
Implementing outbreak control measures requires various activities, including 
notification of the outbreak, exclusion or isolation of varicella case-patients and, if appropriate, 
HZ case-patients, and management of persons without evidence of immunity.  
D.1 Notification of the Outbreak
Notification of an outbreak of varicella and increasing awareness in the affected setting
or community is an important step for controlling the outbreak. For outbreaks in school settings, 
all parents of children attending day care centers or schools where an outbreak occurs should be 
sent a letter that notifies them about the outbreak and provides recommendations on intervention 
measures (e.g., vaccination, exclusion).  In the letter, parents of children without evidence of 
varicella immunity should be advised to have their child vaccinated with the appropriate dose or, 
if vaccination is contraindicated or refused, exclude the child from school up to 21 days after the 
last case is identified. During an outbreak, a second dose of varicella vaccine is also 
recommended for children 1–4 years of age to assist with outbreak control. Parents should 
contact their regular healthcare provider or local health department to vaccinate their child or any 
other household member who needs vaccination. Active identification of persons with
immunocompromising conditions who do not have evidence of immunity to varicella is also 
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recommended so that appropriate control measures can be implemented (e.g., exclude up to 21 
days after the last identified case, provide varicella-zoster immune globulin [VZIG] if indicated). 
Examples of letters notifying parents of a varicella outbreak in a school are available in 
Appendix D. 
Local or state health departments should be notified by schools or healthcare providers 
when cases of varicella are identified. Other healthcare providers in the community should also 
be notified of the outbreak by the local or state health departments through a health alert, asked 
to report varicella case-patients they consult with in the office or by phone, and collect clinical 
specimens to confirm the disease. Notification of varicella outbreaks is also needed for 
residential institution and healthcare settings because of the higher risk for severe disease in the 
populations they serve. Residents, staff, patients, and the local or state health department should 
be notified of outbreaks in such settings. 
As part of the notification, a fact sheet with information about the signs and symptoms of 
varicella, complications from the disease, and basic facts about the vaccine can be provided to 
both parents and healthcare providers. A fact sheet about varicella disease is available at CDC’s 
Vaccines and Preventable Diseases: Varicella (Chickenpox) Vaccination Website, and the 
varicella vaccine information statement is available at Chickenpox Vaccine: What You Need to 
Know . 
D.2 Exclusion or Isolation of Case-patients 
Depending on the setting, isolation of persons with active disease consists of excluding, 
furloughing, or grouping together (cohorting) persons who are ill and are likely to transmit 
varicella until their rash has crusted over. Vaccinated persons with varicella may develop lesions 
that do not crust (macules and papules only). Isolation guidance for these persons is to exclude 
until no new lesions appear within a 24-hour period.  
D.2.a Management of herpes zoster case-patients as potential sources for varicella 
outbreaks
School settings. Immunocompetent persons with HZ can remain at school as long as the 
lesions can be completely covered. Persons with HZ should be careful about personal hygiene, 
wash their hands after touching their lesions and also avoid close contact with others. If the 
lesions cannot be completely covered and close contact avoided, children and staff should be 
excluded from the school setting until lesions have crusted over. If a person has disseminated 
HZ, he or she should be excluded from school until lesions have crusted over (similar to the 
management of varicella case-patients).
Residential institution and healthcare settings. For immunocompetent residents or 
patients with localized HZ, lesions should be completely covered and contact precautions should 
be followed. For immunocompromised persons with HZ or persons with disseminated HZ, the 
management is similar to that of varicella case-patients. 
For healthcare personnel who develop HZ, lesions should be completely covered with a 
taped dressing and, in addition to standard contact precautions, the healthcare worker should be 
removed from direct care of patients at high risk of severe complications from varicella. A 
healthcare worker with disseminated HZ should be excluded from work until lesions have 
crusted over [9]. 
D.2.b Isolation precautions 
In residential and healthcare settings, airborne infection isolation (i.e., negative air-flow 
rooms) and contact precautions should be followed for varicella, disseminated HZ, or localized 
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HZ in an immunocompromised person; standard precautions should be followed for localized 
HZ in an immunocompetent person [47]. If negative air-flow rooms are not available, varicella 
case-patients should be isolated in closed rooms with no contact with persons without evidence 
of immunity. Isolated case-patients should be cared for by staff with evidence of immunity to 
varicella (to determine immune status see section D.3 Management of Persons without Evidence 
of Immunity). 
D.3 Management of Persons without Evidence of Immunity
D.3.a Identification of persons without evidence of immunity 
Identifying persons without evidence of varicella immunity during an outbreak is 
important for preventing the spread of disease and for protecting those at high risk for severe 
disease. 
Information about a history of varicella disease and vaccination should be collected from
all persons in the outbreak setting. Healthcare provider diagnosis or verification of history of 
disease is needed for valid evidence of immunity. Immunization records, data from an 
immunization registry, and records obtained by contacting healthcare providers can be used to 
verify vaccination history. 
Birth in the United States before 1980 is considered evidence of immunity in most cases; 
however, it is not considered as evidence of immunity for healthcare personnel, pregnant women, 
and immunocompromised persons. Epidemiologic and serologic studies have indicated that 
>95% of American adults aged ≥20 years are immune to varicella [CDC unpublished data, 50]. 
In addition, 71–93% of adults with no history or an uncertain history of disease will have VZV 
antibodies when tested [51-55]. Therefore, in healthcare institutions, serologic screening before 
vaccination of personnel who have no history or an uncertain history of varicella and who are 
unvaccinated is likely to be cost effective. State health laboratories offer VZV IgG testing.  
D.3.b Vaccination of persons without evidence of immunity 
Persons without evidence of immunity to varicella and who do not have a 
contraindication to vaccination should be vaccinated. Studies conducted among children showed 
that vaccine administered within 3 days of exposure to rash is most effective in preventing 
disease (≥90%); however, vaccine administered within 5 days of exposure to rash is about 70% 
effective in preventing disease and 100% effective in modifying disease [22,56,57]. In a varicella 
outbreak setting, ongoing exposures are likely and may continue for weeks and even months 
[25]. Thus, to limit disease transmission during an outbreak and to provide protection against 
subsequent exposures, ACIP recommends that all persons without evidence of immunity to 
varicella be offered vaccine even if more than 5 days have passed since first exposure to the 
disease [9]. 
School settings. One dose of the varicella vaccine has been used successfully for 
outbreak prevention and control in school settings [58]. A second dose is now recommended for 
outbreak control [9]. Children who are vaccinated with a first or second dose during an outbreak 
may immediately return to school after vaccination. For outbreaks among preschool–aged 
children in particular, a second dose of varicella vaccine is recommended to provide optimal 
protection for children 1-4 years of age [9]. 
Residential institutions and healthcare settings. These institutions are environments in 
which transmission of VZV is likely to occur, and residents and staff are at high risk for 
exposure. Also, risk of severe disease and complications may be higher among persons without 
evidence of immunity because of age or immune status. Outbreaks in residential institutions can 
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be reduced or prevented if new residents and staff who do not have evidence of immunity are 
vaccinated before moving in or beginning their employment at the institution.  
If exposure occurs in high-risk settings, such as healthcare and certain residential 
institutions, persons without evidence of immunity should be offered varicella vaccine within 3– 
5 days of exposure to varicella rash to provide the greatest protection against developing disease. 
Unvaccinated healthcare workers and staff without evidence of immunity to varicella who are 
exposed to varicella should be furloughed from days 8 to 21 after exposure because they are 
potentially infectious during this period. Postexposure vaccination should be given as soon as 
possible after exposure but vaccination is still indicated >5 days postexposure because it induces 
protection against subsequent exposures. Healthcare workers and staff who have previously 
received one dose of varicella vaccine and have been exposed to varicella should receive the 
second dose within 3–5 days after exposure to rash if more than 4 weeks have elapsed since 
receipt of the first dose. After vaccination, management is similar to that of two-dose vaccine 
recipients. Healthcare workers and staff who have received two doses of varicella vaccine and 
are exposed to varicella should be monitored daily from day 8 to 21 after exposure through the 
employee health program or infection control nurse to determine clinical status (screen for fever, 
skin lesions, and systemic symptoms). Exposed healthcare workers and staff should be instructed 
to immediately report fever, headache, or other constitutional symptoms and any skin lesions and 
should be immediately placed on sick leave if any of these symptoms occur [9].  
D.3.c Management of persons who refuse vaccination 
Children who lack evidence of immunity and whose parents refuse vaccination should be 
excluded from school from the start of the outbreak through 21 days after rash onset of the last 
identified case. Exclusion of persons vaccinated with one dose is difficult to enforce unless 
existing school regulations are in place for a second dose. For example, if a state has a law 
requiring a second dose of varicella vaccine for entry to grades K-3, during an outbreak the 
health department can choose to recommend exclusion of children in grades K-3 with one dose 
who refuse to get vaccinated with the second dose. The second dose can also be recommended 
for children in grades 4 and above but exclusion of one dose recipients would be difficult to 
enforce without the school entry law for those grades. The degree of response with regard to 
exclusion can vary by state and/or jurisdiction. 
D.3.d Management of persons with contraindications to the varicella vaccine 
Persons without evidence of immunity who have contraindications to vaccination (e.g., 
immunocompromised persons, pregnant women) should be excluded from an outbreak setting 
through 21 days after rash onset of the last identified case-patient because of the risk of severe 
disease in these groups. If these persons are exposed to a case of varicella or HZ, VZIG should 
be administered as soon as possible and within 96 hours of exposure [59].  
D.3.e Management of persons with rash developing within 42 days after vaccination 
These persons should be considered as having wild-type VZV unless otherwise 
demonstrated. Rashes occurring within 42 days of vaccination can be due to either incubating 
wild-type VZV or the vaccine strain [60]. Transmission of varicella vaccine virus from a healthy 
person to a susceptible contact is very rare, particularly in the absence of rash in the vaccine 
recipient. Higher risk for transmission of vaccine virus has been documented among children 
who have both rash following vaccination and an immunocompromising condition [61]. 
Transmission has also been documented among children who are immunocompetent but have 
rash following vaccination [62]. If vaccine-associated rash is suspected, every effort should be 
made to determine if the rash is due to vaccine virus or wild-type VZV. The National VZV 
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Laboratory at CDC has the capacity to distinguish between wild-type VZV and the vaccine 
(Oka/Merck) strain. For further information, contact CDC laboratory staff at 404-639-0066 or 
404-639-3667 or email vzvlab@cdc.gov. A Specimen Collection Form must accompany
specimens submitted to the National VZV Laboratory.
If rash following vaccination occurs in a healthcare worker or contact of an 
immunocompromised person, contact with persons without evidence of immunity who are at risk 
for severe disease and complications should be avoided until all lesions have crusted over or no 
new lesions appear within a 24-hour period.  
E. Conduct Case Investigations
After finding all cases and implementing control measures, the next step would be to 
collect information about the case-patients to characterize the illness and outbreak.  
E.1 Information To Obtain from Persons with Varicella (A sample of a case investigation form
is available in Appendix E)
• Name, address, and telephone number(s) to reach the person after the initial interview, if
necessary.
• Demographic information, including country of birth.
• Clinical details, including the following:
Date of rash onset, duration, and severity of rash. Severity can be measured by the 
number of skin lesions (e.g., < 50 [can be counted in 30 seconds], 50–249, 250–499, 
and ≥500 [confluence of lesions in many skin areas]). 
Presence of other symptoms (e.g., fever). 
Complications and/or hospitalizations and death. 
Treatment, if any (e.g., acyclovir). 
History of varicella disease. 
Pre-existing long-term medical conditions (e.g., asthma, cystic fibrosis, cancer, 
HIV/AIDS). 
Medications (e.g., immunosuppressive drugs, aspirin). 
• Vaccination status, including the following:
Number of doses.  
Date(s) of varicella vaccination. 
Provider names and contact information. 
If not vaccinated, describe reason. 
• Source of infection, including the following:
Contact with a probable or confirmed case or a person with a rash illness suspected of
being varicella or HZ and date of exposure. 
Transmission setting (e.g., home, day care center, school, institution). 
• Laboratory information, if clinical specimens are collected, including
− Date and source (e.g., crusts, vesicular fluid) of specimen for viral isolation, PCR, 
and/or DFA. 
Results of PCR, DFA, or viral isolation (positive or negative for VZV). 
Serologic test dates and results. 
If the source of infection is HZ, information about the HZ case-patient should also be 
collected (e.g., onset date of HZ case-patient, age, site of lesions and evolution, underlying 
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medical conditions, contact with varicella case-patients). In residential institution settings, such 
as correctional or training facilities, medical records of case-patients are likely to be available 
and should be used as additional sources of information on illness, treatment during illness, pre-
existing conditions, and prior medications.  
F. Establish Surveillance for Additional Case-patients 
Concomitantly with implementing control measures (i.e., exclusion of case-patients, 
vaccination of persons without evidence of immunity) and collecting data related to the outbreak, 
active surveillance to identify additional case-patients should be established. Cases should be 
considered part of an outbreak if they occur within at least one incubation period (21 days) of the 
previous case-patient, and surveillance should continue through two full incubation periods (42 
days) after the rash onset of the last identified case-patient to ensure that the outbreak has ended.  
F.1 Components of Varicella Surveillance in an Outbreak Setting 
• Reporting should be encouraged from healthcare providers, day cares, schools, colleges, 
and other settings as appropriate, where varicella cases might occur. 
 Establish regular reporting mechanisms (e.g., daily or weekly) using standard 
varicella case investigation forms with hospitals, physicians’ offices, clinics, and/or 
schools to obtain reports of persons with rash illness suspected of being varicella. 
• Distribute guidelines instructing healthcare providers to obtain appropriate clinical 
specimens for laboratory diagnosis (example available at the CDC National VZV 
Laboratory website). 
G. Analyze and Interpret the Data 
Data analyses should be aimed at understanding why the outbreak occurred and at 
providing guidance for control and prevention of future outbreaks. For outbreaks of varicella that 
are investigated, detailed information (e.g., demographics, underlying medical conditions, 
vaccination information) should be collected from both case-patients and persons without 
varicella. As cases of varicella are identified, an epidemic curve illustrating the number of cases 
by date of rash onset will provide a useful picture of the outbreak. Analyses of the data may 
consist of calculations of varicella vaccination coverage rates based on the number of doses (if 
applicable), attack rates by age and other variables of interest (e.g., vaccination status, grade), 
descriptions of the pattern of disease transmission, severity of disease, and the occurrence of 
complications [17,19,34,35,63]. Data should be analyzed throughout the investigation. Vaccine 
effectiveness can also be calculated to determine how well the vaccine is preventing varicella in 
a specific population [see Appendix F for formulas]. For outbreaks involving adolescents or 
adults, describing the impact of the outbreak, including the costs incurred for missed work or 
training, case-patient treatment, and outbreak control, might also be useful for the investigation.  
G.1 Interpretation of the Data 
A high proportion of unvaccinated case-patients is suggestive of low vaccination 
coverage as a cause of the outbreak; a high proportion of vaccinated case-patients is suggestive 
of vaccine failure as a cause of the outbreak. Higher attack rates in one group versus another 
group (e.g., different grades in a school) could suggest different intensities of exposure or 
differences in vaccine coverage. Understanding interactions between case-patients and persons 
without varicella is important for determining risk of exposure. For example, if second and third 
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graders were the only grades in a school that had cases of varicella and they have little to no 
interaction with the other grades in the school, it might be most appropriate to concentrate on 
these two grades for the analysis.
Vaccine effectiveness calculations from outbreak investigations should be interpreted 
carefully. Vaccine effectiveness calculations should focus on vaccinated and unvaccinated 
persons with comparable exposures so that vaccine effectiveness will not be under- or
overestimated. The varicella vaccine does not provide 100% protection; it is expected that cases 
will occur among vaccinated persons, although disease is generally milder than that in 
unvaccinated persons. 
The following risk factors have been identified in various outbreak investigations and 
studies for one dose, but findings are not consistent: age at vaccination, time since vaccination, 
history of asthma, eczema, or steroid treatment, and < 28 day interval between varicella and 
MMR vaccine [19,25,29,31,34,64]. It is difficult to control for the effect of multiple risk factors 
(e.g., age at vaccination and time since vaccination or asthma/eczema and steroid treatment) in 
outbreak investigations because of the small number of case-patients.  
None of the varicella outbreak investigations to date have identified vaccine source, 
storage, or handling as a risk factor for vaccine failure. However, deficiencies in storage and 
handling practices could also result in low vaccine effectiveness in the field. Varicella vaccine, 
either as Varivax or ProQuad (MMRV), has specific storage and administration requirements 
(must be stored at ≤ −15ºC and used within 30 minutes of reconstitution), which could affect the 
effectiveness of the vaccine under field conditions [9,65]. The source of the vaccine and 
determination of whether clustering of cases by provider or clinic has occurred, should be 
examined.  
H. Develop a plan for preventing future varicella outbreaks 
Future varicella outbreaks can be prevented by ensuring high levels of varicella 
immunity, vaccinating persons without evidence of immunity, establishing and maintaining 
varicella surveillance and reporting, and preparing an appropriate response when a case of 
varicella is identified in a particular setting.  
• High levels of varicella immunity can be ensured by 
 Implementing day care, school, and college entry requirements to increase 
vaccination coverage among children, adolescents, and young adults. 
Requiring varicella evidence of immunity in healthcare workers. 
Vaccinating residents of residential institutions who do not have evidence of 
immunity or contraindications to vaccination. 
Vaccinating healthcare, residential institution, and school staff who do not have 
evidence of immunity (or a contraindication to vaccination) before or shortly after 
beginning their employment. 
• Management of single case-patients includes  
Confirming the diagnosis. 
Exclusion or isolation of the case-patient. 
Notification to contacts of possible exposure to varicella case-patient. 
Identifying contacts without evidence of immunity and providing appropriate 
prophylaxis as indicated. 
Conducting surveillance for additional case-patients. 
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  Establishing and maintaining varicella surveillance will ensure that varicella cases are 
identified in a timely manner so that control measures can be implemented for preventing 
further transmission. The recommendation by CSTE to begin case-based reporting of 
varicella cases as of 2005 will help improve the timely identification of outbreaks of 
varicella. As of September 2007, 35 states report conducting varicella case–based 
surveillance. An example of a varicella surveillance worksheet is available in Appendix 
G. 
 
 
 
 
 
 
 
 
 The control and investigation of outbreaks of varicella are important for preventing 
further spread of varicella disease. Strategies for controlling varicella outbreaks include 
confirming the outbreak, identifying cases, implementing varicella control measures, conducting 
case investigations, and establishing surveillance for additional cases. Achieving and maintaining 
high varicella vaccination coverage rates in preschool children with one dose and in school and 
college populations and healthcare workers with two doses will be important to prevent varicella 
outbreaks. Varicella case-based surveillance, including detection of varicella outbreaks, is 
important for documenting the impact of the two-dose varicella vaccination policy and changes 
to varicella epidemiology. Case-based surveillance with collection of additional details of source 
cases, including laboratory confirmation and viral genotyping, will increasingly be needed to 
characterize endemic disease transmission.  Investigations of varicella outbreaks will also help to 
(1) understand why outbreaks continue to occur, (2) develop and refine appropriate public health 
interventions to control varicella outbreaks and prevent future outbreaks, and (3) provide the 
basis for refinements to the varicella vaccination policy. 
 
 
•
VIII. VACCINE 
For detailed information about varicella vaccination and recommendations for use, see 
“Prevention of varicella: recommendations of the Advisory Committee on Immunization 
Practices (ACIP)” 
Reporting of Adverse Events 
The National Vaccine Injury Act of 1986 requires that all physicians and other healthcare 
providers who administer vaccines maintain permanent immunization records and report 
occurrences of adverse events for selected vaccines. Serious adverse events (i.e., all events 
requiring medical attention) should be reported to VAERS. Forms and instructions are available 
at https://secure.vaers.org/vaersDataEntryintro.htm, in the FDA Drug Bulletin at
http://www.fda.gov/medwatch, or by calling (800) 822-7967. 
IX. CONCLUSION 
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XI. Appendix A: Sample varicella outbreak reporting worksheet
Varicella Outbreak Reporting Worksheet
Date of Report to CDC: ___/___/___   
State reporting Name of Person Reporting Phone Email Fax 
Please enter the total number of reported outbreaks for the calendar year in this box  Year of report: ___________ 
If more detailed information about each individual outbreak is available, please enter the information in the table below. 
Out-
brea 
k 
Dates of 
outbreak 
Outbreak 
setting (e.g., 
day care,
elementary, 
middle, high 
school, etc) 
Size of 
outbreak 
(total # of 
cases) 
Number of cases in each 
age group 
Number of 
cases in each 
lesion category 
Vaccination status 
of cases 
Vaccinatio 
n coverage 
in setting 
Number of 
laboratory 
confirmed 
cases in 
outbreak 
# vax # 
unva 
x 
1-
dos 
e 
2-
dos 
e 
1-dose 2-dose 
1 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
2 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
3 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
4 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
5 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
6 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
7 
<1 15-19 <50 
1-4 ≥20 50-249
5-9 Unk 250-499
10-14 ≥500 
Please email or fax this form annually to Adriana Lopez at CDC: alopez@cdc.gov or 404-639-8665 
**PLEASE NOTE: Minimum information requested for reporting is total number of outbreaks per year** 
 
   
 
  
 
 
  
   
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
XII. Appendix B: Sample exposure letters developed by the Connecticut Department of 
Public Health 
A. Sample varicella exposure letter
B. Sample DRAFT herpes zoster exposure letter
To: Parent or Guardian 
From: Director, Daycare X 
Subject: Shingles Exposure at Daycare 
Date: Any Date 
Dear Parent or Guardian: 
This letter is to notify you that a case of shingles has been reported at Daycare X and that your child may
have been exposed. 
Shingles is a form of chickenpox (also known as varicella).  In about 15-20% of persons who get 
chickenpox, the virus will remain in their body in a part of a nerve near the spinal cord.  As a person 
becomes older, the virus may become active again and cause a local, painful rash along the path of that 
nerve. This rash is known as shingles. 
Because shingles results from an earlier chickenpox infection becoming active again within the person, 
shingles is not spread from one person to another.  However, because the same virus causes shingles and 
chickenpox, persons with shingles can spread the chickenpox virus.  In persons with shingles, the virus is 
usually transmitted by contact with fluid from the rash. Those persons who have had chickenpox or have 
received the chickenpox (varicella) vaccine are protected against infection from exposure to shingles.  
Those persons who have not had chickenpox or have not received the chickenpox (varicella) vaccine are 
susceptible to infection from exposure to shingles.  Susceptible persons develop chickenpox rather than 
shingles. Though chickenpox is usually a mild disease, it can be more severe in older persons. 
Daycare X and the Connecticut Department of Health recommend that susceptible individuals contact 
their regular health care provider to seriously consider getting vaccinated now.  Vaccination against 
chickenpox greatly reduces both the mild and serious risks of chickenpox and future shingles and can also 
stop the spread of the chickenpox virus to others who are susceptible. 
A copy of an informational handout from the Connecticut Department of Public Health is included to help 
answer any questions you may have about chicken pox, shingles, and the chickenpox (varicella) vaccine. 
For additional information, please call your health care provider. 
Sincerely,
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XIII. Appendix C: Sample survey to identify cases of varicella in setting  
Please complete this survey and have your child return it to his or her teacher by (insert 
date). All information will be kept strictly confidential.  Your participation is completely 
voluntary; if you do not want to answer any or all questions you don’t have to.  
Parents/Guardians with more than one child in school should fill out a separate survey 
for each child 
ID Number:____________
  (for office use only)
Survey for Parents/Guardians of Children 
1. Name of person completing this form: ___________________________________ 
2. Relationship to child:   □ Parent □ Other (please specify): __________________
3. Child’s Name: _____________________________ 4. Child’s date of birth:  ____/____/____ 
  Child’s Address: ___________________________ Month  Day  Year 
 ____________________Zip code______________ 5. Child’s age: ____________  years
   Parents’ Telephone:  (____)____________ 6. Sex of child: Male Female 
7. Child’s Race/Ethnicity: (Check one) 
African-American Asian/ Pacific Islander Native American/Alaskan Hispanic
White (Caucasian)  Other (please write): ______________________
8. Child’s school (insert name of school): __________________________
9. When did your child first start attending this school?      ____/____ 
Month  Year
10. What grade is your child in this year?_____________  What is the name of his/her teacher? _________________ 
11. Who is your child’s primary care physician? 
Physician: __________________________________________________ 
Address: ___________________________________________________ 
Telephone: (    ) _____________________________________________
12. Has your child received immunizations at other location(s) other than his/her primary care provider office listed above 
in question 11?      □Yes □ No 
12a. If YES, where did your child receive immunizations? ( If more than one location, please provide all  names) 
Name of facility: __________________________________________________________________ 
 Address: _________________________________________________________________________ 
Telephone: (  ) ___________________________________________________________________
13. Do you have an immunization record (shot card) available for your child? (Note-Please do not attach shot card)  
□ Yes □ No 
Please Check Your Immunization Record (Shot Card) to Answer the Next Section. 
If you do not have a shot card, please fill in as much as you remember.
14. Has your child ever received the chickenpox vaccine before the current outbreak? (There are 2 licensed vaccines for 
varicella: [1]VARIVAX, which became available in 1995 and [2]PROQUAD, which became available in 2005)
□ Yes If yes, number of vaccine doses: □ 1 dose □  2 doses  
 Vaccination Date Dose 1:_______/______/________       Vaccine name: □Varivax □Proquad □Unknown 
Month Day  Year 
Provider name : ___________________________  Phone number:  ( ) _____________________ 
  Provider address:_______________________________________________________________________
 Vaccination Date Dose 2:_______/______/________       Vaccine name: □Varivax □Proquad □Unknown 
Month Day  Year 
Provider name: ______________________________  Phone number:  ( )  _____________________ 
  Provider address:_______________________________________________________________________
□ No Please specify why your child has not ever received the chickenpox vaccine before the current outbreak.   
(check all that apply)
□ My child already had chickenpox disease. 
□ I have philosophical or religious beliefs that do not support childhood vaccination against disease. 
□ My child’s doctor/health care provider never offered the chickenpox vaccine for my child.
□ My child has a medical contraindication such that s/he cannot receive the chickenpox vaccine. 
□ Other (please specify): ___________________________________________ 
□ Don’t know
(SURVEY CONTINUES ON BACK)
   
       
   
  
            
               
           
                           
                           
 
     
    
                                          
            
               
            
                   
 
   
         
                                          
            
               
            
            
 
                      
 
        
 
 
 
___________________________________________   __________________________________________ 
                                     
 
 
 
 
15. Does your child have any of the following long-standing health conditions? 
□ asthma  □ eczema □ cancer (specify: ____________________)  □ other (specify: ____________________) 
□ none      □ don’t know
  15a. Does your child currently take any medications prescribed by a physician for this condition? 
□ Yes, please list medication names:_____________________________________________________ 
□ No 
16. Has your child had chickenpox disease since the start of this outbreak (insert date)? □ Yes □ No □ Don’t know
 16b. Who diagnosed the case of chickenpox?  (Check one) 
□ Primary care provider or clinic listed in question  11 or 12a (Please circle which one)       
□ Other physician or clinic, please specify_____________________________________   
□ Parents/friends/ relatives
□ School nurse 
□ Other, please specify ___________________________________________________ 
17. Has your child ever had chickenpox disease prior to this outbreak (insert date)? □ Yes □ No □ Don’t know 
17a. If YES, at what age? _______ Years       OR _______ Months
17b. Who diagnosed the case of chickenpox?  (Check one) 
□ Primary care provider or clinic listed in question  11 or 12a (Please circle which one)       
□ Other physician or clinic, please specify_____________________________________   
□ Parents/friends/ relatives
□ School nurse 
□ Other, please specify ___________________________________________________ 
18. Other than the chickenpox mentioned above, did your child have any rashes, insect bites, bumps, spots, or blisters at 
any time after the start of this outbreak (insert date)? □ Yes □ No □ Don’t know 
19. How can we contact you if further information is needed? 
Phone Number: (         )_________________________     
Best time to call: __________________________________________________________________________________         
20. We would like to verify your child’s vaccination history either from records kept at school or your child’s health care 
provider (or vaccine provider, if different). All information will be kept strictly confidential and will be identified only by
number in our files.   □ I agree to allow verification of my child’s vaccination history    □ I do not agree 
Signature of parent/caregiver       Printed name of parent/caregiver 
THANK YOU FOR COMPLETING THIS SURVEY!
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XIV. Appendix D: Sample letters of notification of varicella outbreaks  
A. Sample varicella outbreak notification letter available from the Connecticut Department of 
Public Health 
B. Example 2 of varicella outbreak notification letter: 
Dear parents/guardians, 
This letter is to notify you that some children attending ______________________ (insert name of 
school) have contracted chickenpox. Varicella causes an acute illness with a rash that results in children 
missing days at school while they have a rash and parents missing work when they stay home to take care 
of their children. Most children now are vaccinated with at least one dose of varicella vaccine but because 
one dose of the vaccine is 80-85% effective for preventing chickenpox, it is not unusual to see 
breakthrough disease. Two doses of varicella vaccine are now routinely recommended for children. 
Background 
Chickenpox is a very contagious infection caused by a virus. It is spread from person to person by direct 
contact or through the air from an infected person’s coughing or sneezing.  It causes a blister-like rash, 
itching, tiredness, and fever lasting an average of 4 to 6 days.  Most children recover without any
problems.  Chickenpox can be spread for 1-2 days before the rash starts and until all blisters are crusted or 
no new lesions appear within a 24-hour period.  It takes between 10-21 days after contact with an infected 
person for someone to develop chickenpox. Chickenpox in vaccinated persons is generally mild, with a 
shorter duration of illness and fewer than 50 lesions. The rash may be atypical with red bumps and few or 
no blisters. 
What should you do? 
__________________ (insert name of health department) strongly encourages you to have your child 
receive their first or second dose of varicella vaccine if your child has not been vaccinated and has never 
had chickenpox. For children who had received 1 dose, a second dose is recommended.  
If your child or anyone in your household currently has symptoms that look like chickenpox: 
1. Contact your regular health care provider to discuss your child's symptoms and to see if anyone in 
the home needs to be vaccinated. 
2. Contact the school nurse to report your child's chickenpox. 
3. Anyone who has chickenpox should avoid contact with others who have not had chickenpox or 
who are not vaccinated against chickenpox. They should not attend school, day care, work, 
parties and/or other gatherings until the blisters become crusted (about 4-6 days after rash 
appears), or no new lesions appear within a 24-hours period.  Keep all chickenpox spots and
blisters and other wounds clean and watch for possible signs of infection; including increasing 
redness, swelling, drainage and pain at the wound site. 
4. If you or anyone else in your household has a weakened immune system or is pregnant and has 
never had chickenpox or the vaccine, talk with your doctor immediately.
  
 
 
 
Controlling the Outbreak 
__________________ (insert name of health department) is working with the school to implement 
prevention strategies. It is now recommended that children with one dose of varicella vaccine receive a 
second dose routinely. If your child does develop chickenpox, he/she should be kept from attending 
school until the rash has crusted over. We are also trying to learn more about why children develop 
chickenpox and how we can best prevent this disease.  In the attached questionnaire, we ask a few 
questions about your child and whether or not he/she has had chickenpox or received the varicella 
vaccine. Please complete and return the questionnaire as soon as possible. 
If you have any further questions or concerns, you can contact (insert name of contact person) or call 
(insert contact phone number). 
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￿ ￿
Date: ________ ￿ Day ￿ Evening Initials: ______  ￿ L/M ￿ N/A-Busy ￿ Wrong# ￿ Disc. ￿ Completed  Init: __ 
Date: ________ ￿ Day ￿ Evening Initials: _______￿ L/M  ￿ N/A-Busy ￿ Wrong# ￿ Disc. ￿ Completed  Init: __ 
Date: ________ ￿ Day ￿ Evening Initials: ______  ￿ L/M ￿ N/A-Busy ￿ Wrong# ￿ Disc. ￿ Completed  Init: __ 
Date: ________ ￿ Day ￿ Evening Initials: _______￿ L/M  ￿ N/A-Busy ￿ Wrong# ￿ Disc. ￿ Completed  Init: __ 
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XV. Appendix E: Sample varicella case investigation form 
Varicella Case Investigation Form 
Case Name:  ID Number:___________________ 
Report Date: 
Database Entry Date: ____________________ 
Call Log:  
Date: ________  Day  Evening Initials: ______  ￿ L/M ￿ N/A-Busy ￿ Wrong# ￿ Disc. ￿ Completed  __ 
Case Status: Probable
Confirmed (check all apply: □ Lab-confirmed  □ Epi-linked to confirmed or probable case) 
Excluded: indicate reason: ______________________________________ 
Pending
Notes:____________________________________________________________________________________ 
Introductory Script Chickenpox Case Form 
Hi, this is__________________.  I am working with the (insert health department name/state). May I speak with the 
parent or guardian of ________________________?  
Hi, this is ____________________. I am working with the (insert health department name/state) and [name of school].
As you may already know, some children in your child’s school have come down with chickenpox over the past month.  
We are contacting all parents or guardians of children who have had chickenpox since the beginning of this school year.  
The (insert health department name/state) is working to determine the best ways to prevent this disease.  I would like to 
ask you some questions about your child’s chickenpox illness.  This will take about 15 minutes.  Are you willing to
answer some questions now or is there a better time to call back?
If NO: best time to call back________________________________________ 
If YES: 
Before we begin, I would like to tell you that all the information that you give to me will be kept confidential.  No names 
will be used in any reports.  Your participation is completely voluntary; you do not have to answer any questions that you 
do not want to.  Whether you decided to answer the survey will not affect your child’s education or healthcare in any way.  
I am happy to answer any questions you have now or during the survey.  Do you have any questions for me now? 
May we start the survey now?
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Case Background Information:
May I have your name please: ________________________________________
What is your relationship to (insert Child’s name): ￿ Parent   ￿ Other ______________________
Did you fill out a parental survey for (insert Child’s name)? ￿ Yes  ￿ No (If Yes, Skip to Question 4)
1. Contact Information 3. Demographics
Address: ___________________________________________ GENDER: Male: ___ Female: ___
City: _______________________________  Zip: RACE:  ￿ African-American/Black 
  ￿ Asian/Pacific Islander  
 ￿ Native American/Alaskan Native Tel: 
 ￿ White  
 ￿ Unknown  
Date of Birth: _____________  ￿Other
2. School Information (if applicable)
School attending: ___________________   Grade: __________ ETHNICITY:   ￿ Hispanic ￿ Non-Hispanic   
￿Unknown
I would like to start by asking some questions about your child’s disease history and medications. 
Case Investigation: 
4. When did you first notice your child’s rash? (Please try to remember the exact date, it is very important. Please 
look at a calendar to help determine date if you are not sure.) ____/____/____  (prompt with date if necessary) 
Month Date Year 
4a. Who diagnosed the current case of chickenpox?  (Check one) 
□ Primary care provider or clinic
□ Other physician or clinic, please specify_____________________________________   
□ Parents/friends/ relatives   
□ School nurse 
□ Other, please specify ___________________________________________________ 
5. Did your child ever have chickenpox before this case of chickenpox?   □ Yes □ No □ Unknown 
5a. If yes, at what age?  _______ Years OR _______ Months 
5b. Who diagnosed the case of chickenpox?  (Check one) 
□ Primary care provider or clinic
□ Other physician or clinic, please specify_____________________________________   
□ Parents/friends/ relatives   
□ School nurse 
□ Other, please specify ___________________________________________________ 
5c. Was your previous chickenpox case lab confirmed?   □ Yes □ No 
6. Was your child ever vaccinated with the varicella vaccine? □ Yes-1 Dose □ Yes-2 Doses   □ No □
Unknown 
6a. If vaccinated, dates of vaccination: Dose 1:_______/______/________ Vaccine: ￿Varivax ￿Proquad ￿Unknown 
   Month Day Year
Dose 2:_______/______/________ Vaccine: ￿Varivax ￿Proquad ￿Unknown
Month  Day  Year
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7. Did your child take any medications prescribed by a doctor during the 30 days before the chickenpox rash 
appeared (include medicines taken by mouth, inhalers, and creams for the skin)? □ Yes □ No 
If Yes, please list the medications and condition(s) the medication was taken for.
What is the name of the 
medication? 
Condition(s) medication taken 
for 
Is this a systemic 
medication (i.e. affects 
the entire body and is 
usually taken orally)?
Yes, No, Unknown 
I am going to continue by asking you several questions about your child’s activities. 
8. Does your child ride to or from school on a bus?  
□ Yes If yes, what is the bus number/neighborhood/name of the bus driver? 
□ No If no, how does your child get to school?______________________ 
9. Does your child attend early care before school? □ Yes □ No If Yes, name facility: ___________________ 
10. Does your child attend extended care after school? □ Yes □ No If Yes, name facility: __________________ 
11. Does your child participate in other activities with other children?   □ Yes □ No 
11a. If yes, what activities has he/she participated in this school year? (check all that apply) 
□ Boys scouts 
□ Brownies/Girls scouts 
□ Church 
□ Sports specify__________________________________________________________ 
□ Physical activity facility  
□ Local library
□ other, please specify___________________________________________ 
□ other, please specify___________________________________________
12. Was your child exposed to anyone with chickenpox or shingles at home or anywhere other than in school in the 
3 weeks before the rash started? □ Yes □ No □ Don’t know
12a. If YES, who was the source of exposure for your child? 
□  Family member or person living in the household □ Friends 
□ Other (specify) _________________________________________________ 
12b. Where was the exposure? ___________________________________________ 
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        15a. Were any macular/popular (red, raised bumps)?               Yes No Unknown            
       15b. Were any vesicular (blisters)?                                             Yes      No      Unknown 
       15c. Was the rash itchy?                                                         Yes      No      Unknown 
       15d. Did the lesions scab?                                                       Yes      No      Unknown        
 
 
         
                                                                                          
___________________ 
 
________________________________ 
 
 
 
 
                     
___________ 
         
 
   
 
  
 
 
              
12c. Was the exposure to someone with chickenpox or shingles? (check correct box): □Chickenpox □Shingles  
12d. What were the date(s) of your child’s exposure to this person? _________________________________ 
(Try to obtain this information on nonschool exposure to chickenpox/shingles that would have occurred 10-21 days 
(ave. 14 days) before rash onset.)
Now I’m going to ask you some specific questions about your child’s chickenpox. 
13. How many days did the rash last, from the start until all blisters scabbed over or no new lesions appeared within a 
24-hour period (for those lesions that did not become scabs)? _____ days
14. At the most severe stage of your child’s chickenpox, how many lesions were present, (read options)? 
□ less than 50 lesions (all could be counted in 30 seconds or less). How many? _______ 
□ 50 lesions to 249 (Some skin was affected, but there was a clear area at least as big as the child’s hand) 
□ 250 lesions to 500 (some skin was affected, but clear areas were not large enough to fit the child’s hand without 
touching other lesions.) 
□ over 500 lesions (many lesions were present, and in some areas you could not see normal skin between areas 
where lesions were found) 
15. How would you characterize the lesions? 
□
□
□
□
□
□
□
□
□
□
□
□
16. Where was the rash on your child’s body, all over or just in one part of the body? 
□  Generalized (all over) 
If generalized, location of rash (check all that apply): □ Face/Head□ Arms □ Trunk □ Legs □Inside Mouth 
□ Palms □ Soles □ Other (specify): 
□  Localized (just in one area of the body), where on the body was the rash?
□  Unknown
17. Did your child have fever at least once during the chickenpox illness?   □ Yes □ No □ Don’t know 
17a. If YES, how was the temperature measured?
□ Tactile (by feel) □ Thermometer  What was the highest temperature that you recorded?
17b. How many days in a row did your child have fever? __________ days
18. How many days was your child sick in bed? __________ days
19. How many days of school did your child miss due to chickenpox? _______________ days
20. Did you contact a health care provider because of your child’s chickenpox? 
□ Yes     □ No □ Don’t know
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20a. If YES, Consulted by Phone? □ Yes □ No If YES,  Date: ____/____/____    
Month Date Year
Seen in office?         □ Yes □ No If YES, Date: ____/____/____    
Month  Date Year
      What is the name of the Provider?_______________________________________
20b.  If consulted, what was the provider’s diagnosis? □ Chickenpox □ Shingles 
□ Another disease (specify): _____________ 
□ Unknown 
21. Was your child treated with acyclovir, famvir, or any licensed antiviral for this case of chickenpox? 
□ Yes □  No □ Don’t know 
21a. If YES, what is the name of the medication? _______________________________ 
Start date: _____/_____/_____      Stop date: _____/_____/_____ 
Month    Date   Year Month     Date  Year 
22. Were there any complications from this case of chickenpox?  
□  None □  Skin infection   □ Cerebellitis/Ataxia □ Encephalitis □ Pneumonia □ Hemorrhagic Condition  
□  Other complications (please specify) ______________________________ 
23. Was your child hospitalized because of chickenpox or one of its complications?  
□ Yes □ No □ Don’t know 
23a. If YES, how many days was your child hospitalized? ___________________ 
      23b. Which hospital was your child taken to?   Hospital: ____________________________________________ 
  City, State: 
24. Was a specimen collected from your child to verify this case of chickenpox?
□  Yes □  No □ Don’t know 
If YES, please complete table below. 
Type of specimen (e.g., 
scab, saliva, blood, 
environmental) 
Date specimen 
collected 
Test Location 
(i.e., state lab, 
CDC, commercial 
lab) 
Lab Test (i.e., 
DFA, PCR, IgG 
ELISA, IgM 
ELISA) 
Lab Results (i.e., positive, 
negative, indeterminate) 
NOTE TO INTERVIEWER:  For newly identified cases, please ask if parent will give permission to collect a 
specimen from their child to verify child’s varicella disease. The parent will be informed about the results of the 
test and all information will be kept strictly confidential and only identified by number in our files.  
Permission granted: Yes ______    No ______
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For accurate estimation of the VE, calculations should generally include only persons 
with: 1) no history of varicella disease (those with unknown history are excluded from the 
calculation); 2) accurate vaccination information (if vaccinated); and 3) timely vaccination 
(vaccinated at ≥12 months of age, vaccinated ≥42 days before the start of the outbreak, and at 
least 3 month interval between 1st and 2nd dose in children <13 years of age; 4-8 week interval in 
persons ≥13 years of age). 
 
XVI. Appendix F: Useful formulas for the investigation of varicella outbreaks 
1) Varicella vaccination  = # of children who have received x doses varicella vaccine
coverage rate                     Total # of children eligible to receive x doses of vaccine in  
       the study population 
2) Attack rate calculations: 
Vaccination status at start of outbreak 
Varicella during the 
outbreak 
Vaccinated Unvaccinated Total 
Yes a b a+b 
No c d c+d 
Total a+c b+d a+b+c+d 
a = number of vaccinated cases (either with one or two doses) 
b = number of unvaccinated cases 
c = number of vaccinated non-cases (either with one or two doses)  
d = number of unvaccinated non-cases. 
ARV = Attack Rate vaccinated  = a/(a+c) 
ARU = Attack Rate unvaccinated  = b/(b+d) 
3) Vaccine effectiveness calculations: 
     Vaccine effectiveness (VE) %  = Attack Rate unvaccinated – Attack Rate vaccinated  X 100 
      Attack  Rate  unvaccinated 
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XVII. Appendix G: Sample of varicella surveillance worksheet 
A. Varicella surveillance worksheet developed by CDC as a guide for states to use for varicella 
case-based surveillance.  
￿ 
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This document can be found on the CDC website at: 
www.cdc.gov/chickenpox/outbreaks/downloads/manual.pdf 
